Event Participants
Executives
2 Bhushan Akshikar, Ronojit Biswas
Analysts
8 Ahmed Madha, Gokul Maheshwari, Pranav Chawla, Rajat Srivastava, Ronak Chheda, Vamsi Krishna Hota, Vishal Manchanda, Yash Doshi
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹924 crores | Up 15% YoY; headline inflated ~4-5% by favorable base from prior-year CMO disruptions; sustainable growth ~9-10% |
| Volume Growth | ~3-3.5% blended | Balanced across portfolio; price contributed ~6%, balance from new product introductions |
| EBITDA Growth | +17% YoY | 2pp ahead of sales; margins expanded 50 bps YoY |
| EBITDA Margin | ~34% (FY27 guidance) | 50 bps YoY improvement; gross margin expansion of ~150 bps driven by pricing and product mix, partially offset by rupee depreciation on imports |
| PAT | ₹253 crores | Up 24% YoY; includes one-off dividend from subsidiary Biddle Sawyer — ex that, growth ~17% |
| PAT Margin | 27.6% | Expanded 200 bps YoY |
| EPS | ₹14.95 | For the quarter |
| Spend-to-Sales Ratio | +~1pp YoY | Deliberate Q1 front-loading of direct marketing (3,800 HCP events); expected to moderate to historical trends |
| Innovation Portfolio Contribution | 7% of revenue | Up from 4% YoY; contributed ~4pp of headline growth |
| Shingrix Growth | ~65% YoY | 45,000-50,000 doses per quarter; crossed ₹100 crores on MAT basis |
| Nucala Patient Addition | ~100-120 patients/month | Doubled from 50-60 patients/month in prior-year quarter; ~600 active patients |
| Oncology Patients Treated | ~260-270 patients (Q1) | Combined Zejula + Jemperli; ~600-700 patients in first half of calendar 2026 |
Geographic & Segment Commentary
General Medicines: All brands posted IQVIA efficacy indices of 105-106, growing ahead of the market; double-digit growth sustained despite ~44-45% of the portfolio being under price control. This remains the cash engine and scale foundation of the business.
Vaccines: Market leadership retained in private pediatric vaccines and the adult vaccination segment. Shingrix delivered 65% growth on the back of HCP engagement and adult ecosystem building; a couple of vaccines faced availability phasing issues expected to correct in Q2.
Specialty (Respiratory & Oncology): Nucala nearly doubled new patient starts YoY; Trelegy Ellipta held 10,000-12,000 monthly units despite 10-12 generic entrants. Oncology portfolio (Zejula for ovarian, Jemperli for endometrial) touched 260-270 patients in Q1, both brands among top-5 in their respective categories.
Innovation Portfolio: IP-protected assets now contribute 7% of total revenue (vs. 4% last year), contributing ~4pp to headline growth — products that did not exist three years ago.
Company-Specific & Strategic Commentary
Portfolio Transformation: GSK India is executing a deliberate shift toward specialty and innovation, launching global pipeline assets rapidly — Blenrep (belantamab mafodotin for relapsed/refractory multiple myeloma) expected in next 2-3 months with second-line indication, and Arexvy (first adult RSV vaccine) already received marketing authorization.
Pipeline Acceleration: Bepirovirsen, a potential functional cure for chronic hepatitis B, is on track for launch within the next three quarters; India was part of the global B-Well trial, and management is building the patient funnel and stakeholder roadmap.
Go-to-Market Model: Omnichannel approach supplements 2,000+ field force with digital HCP engagement; a super-distributor arrangement (Go Apptiv) covers tail-end products for deeper Tier 3/4 reach. Incremental hiring focused on oncology and hematology (~40-45 reps), with future expansion into liver disease.
Manufacturing & Supply Chain: Local-for-local model — bulk of GenMed manufactured at Nashik facility plus 20 contract manufacturers; post-CMO incident, business continuity plans strengthened and the worst is behind.
Parent Alignment: Despite global restructuring at GSK PLC, India remains a high-growth market with double-digit GenMed performance; India is securing earlier access to global clinical trials, reducing launch lag.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | Double-digit (sustainable); INR8,000 crores in 4-5 years | Intent to sustain double-digit momentum; 2x vision intact — GenMed 8-10% plus innovation arrowheads |
| EBITDA Margin | ~34% range for FY27 | SG&A ratios to normalize to historical levels after Q1 front-loading; gross margin expansion and cost discipline support |
| GenMed Growth | 8-10% | Base business remains relevant and growing ahead of market with EI 105-106 |
| Blenrep Launch | Q2-Q3 FY27 (within 2-3 months) | Marketing authorization received; second-line multiple myeloma; team already trained |
| Bepirovirsen Launch | Within next 3 quarters | B-Well trial data supportive; patient funnel and stakeholder work underway |
| Innovation Portfolio Mix | Rising contribution | From 7% of revenue currently; oncology, respiratory and adult vaccines driving |
Risks & Constraints
| Risk | Context |
|---|---|
| Rupee Depreciation | Hardening of imported purchase costs; net-offset by pricing and product mix in Q1. Management sees no immediate externalities impacting supply chain due to well-embedded global sourcing. |
| Category Creation for Adult Vaccines | Arexvy (RSV) and Shingrix require educating HCPs and building adult vaccination awareness — an invest-heavy, multi-quarter journey. Management noted 10-12 million eligible 50+ adults with disposable income. |
| Generic Competition | Trelegy Ellipta faces 10-12 generic entrants for umeclidinium; brand holding via device innovation and market share retention, but competitive intensity remains. |
| Price Control | ~44-45% of GenMed portfolio is under NLEM price control; pricing flexibility limited, growth must come from volume and new introductions. |
| Opex Front-Loading | Q1 spend-to-sales up ~1pp with 3,800 HCP events — deliberate concentration before peak Q2 season; risk if investments don't convert to sustained growth in following quarters. |
| Launch Execution Risk | Blenrep, Arexvy, Bepirovirsen timelines dependent on regulatory approvals, market readiness and clinical trial progress; any slippage impacts the 2x revenue target trajectory. |
Q&A Highlights
Parent Restructuring & India Strategy
- Question: Does GSK PLC's global restructuring with specialty focus hamper investment in India given the GenMed-heavy portfolio? (Gokul Maheshwari)
- Answer: India is one of the few markets with double-digit GenMed growth — brands are trustmarks. GSK has accelerated India's inclusion in global clinical trials (60+ trials up to 2031), reducing launch lag. Blenrep for second-line multiple myeloma addresses significant unmet need (~19,000 new patients annually). India is "suitably structured" having already undergone restructuring in prior years. (Bhushan Akshikar)
Supply Chain Recovery (Calpol)
- Question: How much lost sales from CMO disruptions have been recouped; is winning back market share difficult? (Gokul Maheshwari)
- Answer: Worst is behind. Learnings from the CMO incident were used to stress-test the entire supply chain; underlying adjusted growth remained double-digit. Business continuity plans strengthened. (Bhushan Akshikar)
Super-Distributor for Deep Reach
- Question: How is GSK ensuring distribution depth in Tier 3/4 markets vs. peers using services like Go Apptiv? (Gokul Maheshwari)
- Answer: GSK already uses Go Apptiv as a super-distributor for tail-end products to access remote interiors, ensuring iconic brands remain available and accessible in deep markets. (Bhushan Akshikar)
Q2 Acute Season Outlook
- Question: Q2 is peak acute season; last two years were weak — what are current trends? (Ronak Chheda)
- Answer: Acute segments contribute ~60% of the pharma market. June-July data points tracking in line with expectations; broad-based seasonal upswing in last 4-6 weeks gives confidence Q2 will be in line. (Bhushan Akshikar)
Shingrix & Respiratory Portfolio Scale-up
- Question: Can you share Shingrix and Nucala YoY growth and Shingrix dose numbers? (Vishal Manchanda)
- Answer: Shingrix grew 65% in Q1, selling 45,000-50,000 doses per quarter; INR100 crore+ brand on MAT basis confirmed. Nucala doubled new patient starts to 100-120/month; ~600 active patients. Trelegy holds at 10,000-12,000 monthly units despite 10-12 generics. (Bhushan Akshikar)
Opex Investment Run-Rate
- Question: Is the opex spike a one-off or will it continue as a % of turnover? (Yash Doshi)
- Answer: Deliberate Q1 concentration — ~3,800 HCP events, international speaker meets, focused on oncology, adult vaccination and pediatric vaccines, timed before the biggest revenue quarter (Q2). Expected to moderate and return to historical trends in following quarters. (Ronojit Biswas)
Blenrep & Bepirovirsen Timelines
- Question: Will Belantamab and Bepirovirsen be commercialized in FY27 or FY28? (Yash Doshi)
- Answer: Blenrep — CDSCO approval received for second-line relapsed/refractory multiple myeloma (~7,000-8,000 patients); launch in next 2-3 months (Q2, else Q3). Bepirovirsen — India was in B-Well trial; launch within next three quarters, with roadmap and patient funnel work underway. (Bhushan Akshikar)
Oncology Scale-up & Rep Productivity
- Question: How are Jemperli and Zejula scaling; what's current MR productivity and hiring plans? (Yash Doshi)
- Answer: Combined oncology brands touch 600-700 patients in first half of calendar 2026 (250-300/quarter). Examples of patients in complete remission on 12-13 cycles of Jemperli. Blended rep productivity INR15-16 lakhs per rep (improved 5-6% YoY). Hiring focused on new therapeutic areas — hematology team added, liver disease next. Oncology team of ~40-45 reps. (Bhushan Akshikar)
2x Vision Roadmap (INR8,000 crores)
- Question: Does the INR8,000 crore top-line target (13-14% CAGR) come from current portfolio or new pipeline? (Rajat Srivastava)
- Answer: GenMed must sustain 8-10% growth; innovation assets in high-growth segments (oncology grew 27% in Q1 vs. industry 12-13%) will be the arrowheads. Bolting growth platforms onto the established foundation keeps the 2x vision intact. (Bhushan Akshikar)
Bepirovirsen Commercial Model
- Question: For patients not cured by bepirovirsen, would it become chronic therapy; how does pricing work? (Ahmed Madha)
- Answer: Fundamentally yes — cured patients use short-term therapy, non-cured patients may need continued treatment. India has 40M+ chronic hepatitis B patients. Management is building the patient funnel and will share specifics (patient segmentation, pricing) at Q2 results. Functional cure concept is new — details being finalized. (Bhushan Akshikar)
Growth Decomposition & Input Costs
- Question: Break-up of pricing vs. volume growth; any raw material pressure post West Asia war? (Gokul Maheshwari)
- Answer: Volume ~3-3.5%, price ~6%, balance from new introductions. No immediate raw material or packaging material pressures — supply chains well-embedded globally, externality impact not visible near-term. (Bhushan Akshikar)
EBITDA Margin Sustainability
- Question: With imported innovative drugs having lower margin contribution, are EBITDA margins sustainable? (Yash Doshi)
- Answer: SG&A ratios to normalize to historical levels; EBITDA margins guided to ~34% for the year, similar to last year. Balance between established portfolio and new assets will drive both growth and profitability. Primary objective is top-line growth while maintaining current margin profile. (Ronojit Biswas)
Key Takeaway
GSK India delivered a strong start to FY27 with revenue of ₹924 crores (+15% YoY, ~9-10% ex-base effect) and PAT of ₹253 crores (+24%; ~17% ex one-off), while EBITDA grew 17% with 50 bps margin expansion. The portfolio transformation is accelerating — innovation assets now contribute 7% of revenue (vs. 4% last year) and drove ~4pp of growth, with Shingrix up 65% and oncology touching 260-270 patients in the quarter. Management reaffirmed the INR8,000 crore revenue target in 4-5 years, anchored on double-digit GenMed growth (EI 105-106) plus near-term launches of Blenrep (multiple myeloma, Q2-Q3 FY27), Arexvy (RSV vaccine), and Bepirovirsen (hepatitis B functional cure, within three quarters). EBITDA margins guided to ~34% for the year as Q1 opex front-loading normalizes. Key watch items: conversion of 3,800 HCP investments into Q2 peak-season growth, rupee depreciation impact on imported inventories, and execution of adult vaccine category creation.